Abstract library

4 results for "Herbst".
#805 Clinically Detected Gastroenteropancreatic Neuroendocrine Tumors are on the Rise: Epidemiological Changes in Germany
Introduction: -
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr. med. Jan Eick
Keywords: GEP-NET, Germany
#1196 CBEZ235Z2401: Randomized Phase II Study of BEZ235 or Everolimus (EVE) in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET)
Introduction: EVE is an mTOR inhibitor (mTORi) approved for the treatment of advanced pNETs. BEZ235, a dual mTOR/PI3K inhibitor, may provide greater PI3K pathway inhibition and enhanced antitumor effects.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Steven Libutti
Keywords: pNET, BEZ235, everolimus
#2112 Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials
Introduction: Hyperglycemia and hypercholesterolemia are class effects of mTOR inhibitors such as everolimus (EVE).
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Nicola Fazio
Authors: Fazio N, Carnaghi C, Buzzoni R, Valle J, ...
#2115 Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials
Introduction: NETs are extremely heterogeneous in nature. Despite recent advances, few biomarkers are available to consistently predict prognosis and optimize treatment selection.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: David L Chan